Verified Nov 2026
Other
·

Warren, New Jersey
·
Since 1998
PTC Therapeutics, Inc. is a biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey, with 1,000–5,000 employees and an estimated revenue band of $1–5 billion. The company discovers, develops, and commercializes medicines for rare and serious diseases, particularly those affecting neurology and metabolism. It completed the acquisition of ST-920, a Fabry disease gene therapy program, in September 2026.
PTC Therapeutics, Inc. at a glance
Revenue
$1-5B
Est. band
Employees
1,000-5,000
Founded
1998
Headquarters
Warren, New Jersey
Import activity
7
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
7
Named foreign suppliers
3
Top origins
Spain

Shared foreign counterparties do not establish that these companies buy from PTC Therapeutics, Inc..
What this tells a buyer
The company received 7 total recorded shipments, with top suppliers located in Spain, including Laboratorios Farmaceuticos Rovi S A and Rovi Pharma Industrial Services.
PTC Therapeutics develops therapies targeting post-transcriptional control mechanisms, with marketed products including Translarna, Emflaza, and Evrysdi for conditions such as Duchenne muscular dystrophy and spinal muscular atrophy.
The board authorized a $500 million share repurchase program in November 2026, reflecting the company's capital allocation strategy.
Source: US customs bill-of-lading records and public filings · Last verified Nov 16, 2026
STABILITY SIGNALS
Established & active
28 years in operation (founded 1998).
7 US import shipments on record.
Overview
PTC Therapeutics, Inc. is a biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey, with 1,000–5,000 employees and an estimated revenue band of $1–5 billion. The company discovers, develops, and commercializes medicines for rare and serious diseases, particularly those affecting neurology and metabolism. It completed the acquisition of ST-920, a Fabry disease gene therapy program, in September 2026.
At a glance
Attribute | Detail |
|---|---|
Founded | 1998 |
Headquarters | Warren, New Jersey |
Employees | 1,000-5,000 |
Revenue | $1-5B (estimated) |
What PTC Therapeutics, Inc. makes
PTC Therapeutics develops therapies targeting post-transcriptional control mechanisms, with marketed products including Translarna, Emflaza, and Evrysdi for conditions such as Duchenne muscular dystrophy and spinal muscular atrophy.
Products and capabilities described on the company's own site include LED (source: ptcbio.com).
Trade and customs footprint
The company received 7 total recorded shipments, with top suppliers located in Spain, including Laboratorios Farmaceuticos Rovi S A and Rovi Pharma Industrial Services. US customs bill-of-lading records list 7 inbound shipments across 3 foreign suppliers, with top origins including Spain.
Latest developments
2026-11-03 — PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program | PTC Therapeutics. (ptcbio.com)
2026-10-29 — PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results | PTC Therapeutics. (ptcbio.com)
2026-09-21 — PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy | PTC Therapeutics. (ptcbio.com)
2026-08-12 — PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program | PTC Therapeutics. (ptcbio.com)
2026-07-30 — PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | PTC Therapeutics. (ptcbio.com)
2026-06-09 — PTC Therapeutics va investir 45 millions d’euros pour la production d’un médicament pour la phénylcétonurie dans l’Ain (lejournaldesentreprises.com)
Company details
The board authorized a $500 million share repurchase program in November 2026, reflecting the company's capital allocation strategy. PTC Therapeutics, Inc. was founded in 1998, has an estimated 1,000-5,000 employees, and is headquartered in Warren, New Jersey. On the LightSource stability read it is rated "Established & active": 28 years in operation (founded 1998). 7 US import shipments on record.
Frequently asked questions
What does PTC Therapeutics, Inc. do?
PTC Therapeutics, Inc. is a biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey, with 1,000–5,000 employees and an estimated revenue band of $1–5 billion. The company discovers, develops, and commercializes medicines for rare and serious diseases, particularly those affecting neurology and metabolism. It completed the acquisition of ST-920, a Fabry disease gene therapy program, in September 2026.
Where is PTC Therapeutics, Inc. headquartered?
PTC Therapeutics, Inc. is headquartered in Warren, New Jersey (Warren Corp Center Dr, Warren, New Jersey, 07059).
When was PTC Therapeutics, Inc. founded?
PTC Therapeutics, Inc. was founded in 1998.
How big is PTC Therapeutics, Inc.?
PTC Therapeutics, Inc. has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).
Does PTC Therapeutics, Inc. import from overseas suppliers?
US customs bill-of-lading records show 7 inbound shipments for PTC Therapeutics, Inc., with top origins including Spain.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
